Tongue hyperpigmentation during hepatitis C treatment.

1498 CMAJ, September 18, 2012, 184(13) © 2012 Canadian Medical Association or its licensors A47-year-old black woman with chronic hepatitis C (genotype 4) was referred for hyperpigmentation of the tongue. She was a nonsmoker. Eight weeks after treatment with weekly injections of subcutaneous pegylated interferon α-2a and daily oral ribavirin was started for hepatitis C, asymptomatic dark brown patches developed on the dorsum and the apex of her tongue (Figure 1). No other sites were involved. Laboratory examination showed neutropenia with a neutrophil count of 0.88 (normal 1.5–7.0) × 10/L. Investigations including liver enzymes, cortisol and thyroidstimulating hormone were normal. In the ab sence of an alternative explanation, an adverse effect of treatment was suspected. The treatment course with interferon and ribavirin was continued until its completion at 48 weeks. During this time, there was a slight increase in hyperpigmentation. Hyperpigmentation of the tongue is an un common adverse effect of combination therapy with pegylated interferon and ribavirin for hepatitis C, described mainly in dark-skinned patients. In one series, it was observed in 5 of 171 dark-skinned patients versus none in 149 white patients. However, instances in white patients have also been reported. This adverse effect usually develops within the first few months of treatment, and improves or disappears slowly after the end of therapy. The hyperpigmentation is usually asymptomatic, but a burning sensation may be reported. Associated involvement of the gums and oral mucosa, and hyperpigmentation of the skin have been described. Histologic examination shows increased amounts of melanin in the basal layer of the epithelium. Upregulation of melanocyte-stimulating hormone receptors by interferon-α is suspected, which increases tyrosinase activity in melanocytes and tyrosine, the main precursor of melanin. The differential diagnosis includes Addison disease, Peutz–Jeghers syndrome, Laugier–Hunziker syndrome, amalgam tattoo, nevi, lichen planus pigmentosus, and adverse reactions to other medications, such as chloroquine and minocycline.